Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Freeman-Keller, Morganna, Kim, Youngchul, Cronin, Heather, Richards, Allison, Gibney, Geoffrey, Weber, Jeffrey S.·2016·Clinical Cancer Research
DOI 10.1158/1078-0432.ccr-15-1136

Cited by (860)

Items 801–860 of 860

  1. Data from Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors
    Maria Grigoriou, Aggelos Banos, Aikaterini Hatzioannou, Andreas Kloetgen, Panagiotis Kouzis, Despoina Aggouraki, Roubini Zakopoulou, Giorgos Bamias, Eva N. Kassi, Dimitriοs Mavroudis et al. · 2023
  2. Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysis
    Yuhao Wei, Yun Hong, Xueyan Zhou, Hang Wang, Rui Zhao, Xuelei Ma · 2023 · Research Square
  3. Drawbacks of immune checkpoint inhibition and rigorous management for immune-related adverse events along with a mathematical model to assess therapy success and optimum therapy duration and a strategy against tumor plasticity
    C. Mehmet Hendekli · 2023 · Journal of Cancer Research and Clinical Oncology
  4. Influence of Antibiotic Use on the Effectiveness and Safety of Immune Checkpoint Inhibitors
    Takuya Minamishima, Hirotake Hida, Masayuki Miyazaki, Shunsuke Kon, Koji Senzaki, Taku Nagai, Kiyofumi Yamada · 2022 · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
  5. Complete Atrioventricular Block Smartwatch Enhanced Diagnosis in Lyme’s Carditis: A Case Report and an M-Health Utilization
    Marzia Giaccardi, Federico Turreni, Piercarlo Ballo, Loreno Querceto, Aladino Ibrahim, Stella Cartei, Elena Crudeli, Tania Chechi · 2023 · Annals of Case Reports
  6. Data from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
    Evan Rosenbaum P. E, Kenneth P. Seier, Martina Bradić, Ciara Marie Kelly, Sujana Movva, Benjamin Alexander Nacev, Mrinal M. Gounder, Mary Louise Keohan, Viswatej Avutu, Ping Chi et al. · 2023
  7. Data from Immune-related Adverse Events after Immune Checkpoint Blockade–based Therapy Are Associated with Improved Survival in Advanced Sarcomas
    Evan Rosenbaum P. E, Kenneth P. Seier, Martina Bradić, Ciara Marie Kelly, Sujana Movva, Benjamin Alexander Nacev, Mrinal M. Gounder, Mary Louise Keohan, Viswatej Avutu, Ping Chi et al. · 2023
  8. Kutane Nebenwirkungen unter Immun-Checkpoint-Inhibitor-Therapie
    Franziska Grän, Bastian Schilling · 2023 · Aktuelle Dermatologie
  9. A Case of Pembrolizumab-induced Autoimmune Encephalitis Developing During Treatment for Nasopharyngeal Cancer
    Wataru Hojo, Gaku Takano, Daisuke Kawakita, Takuma Matoba, Keisuke Oguri, Akihiro Murashima, Kiyoshi Minohara, Kazuyuki Nakai, Sho Iwaki, Hiroshi Tsuge et al. · 2023 · Practica Oto-Rhino-Laryngologica
  10. Immune Checkpoint Inhibition
    James M. Isaacs, Afreen Idris Shariff, Jeffrey Crawford · 2023 · Springer eBooks
  11. CTLA-4 Inhibitors for the Treatment of Lung Cancer
    Shvetank Bhatt, Shreya Sharma, Shubham Patil, Rohini Pujari · 2024 · Springer eBooks
  12. Immune Checkpoint Inhibition
    James M. Isaacs, Afreen Idris Shariff, Jeffrey Crawford, Michel Georges Khouri, Meenal Kheterpal, Sarah LeNoir Sammons, Michelle Ferreira, April Wall, Jane E. Onken, Lindsay King et al. · 2024 · Springer eBooks
  13. Efficacy of adjuvant immune checkpoint inhibitors in melanoma patients ≥75 years – results of a real-world cohort including 456 patients
    Andrea Gawaz, Isabel Wolff, Lukas Flatz, Andrea Forschner · 2024 · Research Square
  14. Biomarkers for response to immune checkpoint inhibitors in metastatic melanoma
    Thijs T. Wind · 2024
  15. Identification of risk factors for gastrointestinal immune–related adverse events associated with immune check point inhibitors
    Ryo Morikawa, Kentaro Nitta, Shuntaro Yasuda, Yoshihito Kano, Rika Noji, Satoru Aoyama, Shingo Sato, Sadakatsu Ikeda, Ryuichi Okamoto, Masashi Nagata et al. · 2024 · Expert Opinion on Drug Safety
  16. Managing adverse effects of novel immunotherapies in pancreatic and colon cancers
    Zohaib Ahmed, Syed Osama Ahmad, Sarfraz Ahmad · 2025 · Elsevier eBooks
  17. Focusing on antigen-specific T cells
    Takashi Inozume, Satoshi Fukushima · 2025 · British Journal of Dermatology
  18. Bullous pemphigoid following radiotherapy combined with ipilimumab-nivolumab therapy
    Anna Pankakoski, J. Panelius, Nicolas Kluger · 2025 · Annales de Dermatologie et de Vénéréologie
  19. Pembrolizumab-induced pemphigoid nodularis manifesting as an erythema multiforme-like eruption: a case report
    Linzhu Kang, Ji Hye Yang · 2025 · Clinical Cancer Bulletin
  20. Lack of Association Between Glucose Homeostasis and Immune Checkpoint Inhibitor Outcomes: A Retrospective Institutional Review
    J. B. Justice, Hannah Burnette, Rebecca T. Irlmeier, Fei Ye, Douglas Buckner Johnson · 2025 · Cancers
  21. Pulmonary Side Effects of Immunotherapy
    Cihan Erol, Mehmet Alı Nahıt Şendur · 2025 · Springer eBooks
  22. Bedeutung des löslichen IL‐2‐Rezeptors in der Diagnostik sarkoidoseähnlicher Reaktionen bei Melanompatienten unter Immuntherapie – ein diagnostischer Algorithmus basierend auf einer monozentrischen retrospektiven Studie
    Philipp Gussek, Julia Mentzel, Maxime Ablefoni, Mirjana Ziemer · 2025 · JDDG Journal der Deutschen Dermatologischen Gesellschaft
  23. Association between treatment-related adverse events and clinical outcomes in NSCLC patients receiving neoadjuvant immunochemotherapy: a retrospective study
    Maoduo Zhang, Y. Li, Lei Guo, Haifeng Lin, Xiao qing Cao, Zhexin Ding, Yi Han, Hezhe Lu · 2025 · Current Medical Research and Opinion
  24. Amelanotic melanoma of the central nervous system with systemic spread – imaging pitfalls and clues in a rare paediatric case with congenital melanocytic naevi
    Xin Yuan Tan, Daniel Jing Wen Teh, Timothy Shao Ern Tan · 2025 · Child s Nervous System
  25. Additional file 1 of Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Liu, Xin, Su Li, Liyuan Ke, Cui, Hongxia · 2024 · Figshare
  26. Additional file 2 of Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
    Zhou, Xiaoxiang, Yao, Zhuoran, Yang, Huaxia, Liang, Naixin, Zhang, Xuan, Zhang, Fengchun · 2020 · Figshare
  27. Additional file 6 of Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Liu, Xin, Li, Su, Liyuan Ke, Cui, Hongxia · 2024 · Figshare
  28. Additional file 3 of Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Liu, Xin, Li, Su, Liyuan Ke, Cui, Hongxia · 2024 · Figshare
  29. Additional file 1 of Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis
    Teppei Yamaguchi, Shimizu, Junichi, Hasegawa, Takaaki, Yoshitsugu Horio, Inaba, Yoshitaka, Hanai, Nobuhiro, Muro, Kei, Hida, Toyoaki · 2021 · Figshare
  30. Additional file 1 of Correlation between immune-related adverse events and efficacy of PD-(L)1 inhibitors in small cell lung cancer: a multi-center retrospective study
    Zhang, Jian, Aiqin Gao, Shuyun Wang, Yanxin Sun, Wu, Jiake, Wang, Dahai, Yihui Ge, Li, Juan, Haifeng Sun, Qinglei Cheng et al. · 2024 · Figshare
  31. Additional file 11 of Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Liu, Xin, Li, Su, Liyuan Ke, Cui, Hongxia · 2024 · Figshare
  32. Additional file 12 of Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Liu, Xin, Su Li, Liyuan Ke, Cui, Hongxia · 2024 · Figshare
  33. Additional file 2 of Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
    Yang, Fan, Chloe Shay, Marin Ibrahim Abousaud, Chris Tang, Li, Yamin, Qin, Zhaohui, Saba, Nabil F., Teng, Yong · 2024 · Figshare
  34. Additional file 1 of Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
    Yang, Fan, Chloe Shay, Marin Ibrahim Abousaud, Chris Tang, Li, Yamin, Qin, Zhaohui, Saba, Nabil F., Yong Teng · 2024 · Figshare
  35. Additional file 5 of Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Liu, Xin, Li, Su, Liyuan Ke, Cui, Hongxia · 2024 · Figshare
  36. Additional file 9 of Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Liu, Xin, Su Li, Liyuan Ke, Cui, Hongxia · 2024 · Figshare
  37. Additional file 10 of Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Liu, Xin, Li, Su, Liyuan Ke, Cui, Hongxia · 2024 · Figshare
  38. Additional file 4 of Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Liu, Xin, Su Li, Liyuan Ke, Cui, Hongxia · 2024 · Figshare
  39. Additional file 2 of Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Liu, Xin, Li, Su, Liyuan Ke, Cui, Hongxia · 2024 · Figshare
  40. Additional file 1 of Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
    Zhou, Xiaoxiang, Yao, Zhuoran, Yang, Huaxia, Liang, Naixin, Zhang, Xuan, Zhang, Fengchun · 2020 · Figshare
  41. Additional file 8 of Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Liu, Xin, Li, Su, Liyuan Ke, Cui, Hongxia · 2024 · Figshare
  42. Additional file 7 of Immune checkpoint inhibitors in Cancer patients with rheumatologic preexisting autoimmune diseases: a systematic review and meta-analysis
    Liu, Xin, Li, Su, Liyuan Ke, Cui, Hongxia · 2024 · Figshare
  43. Développement d’un modèle humain de mélanome ex vivo basé sur l’implantation de sphéroïdes dans des explants de peau
    C. Jardet · 2016
  44. Ρarticularité cliniques et impacts thérapeutiques des effets indésirables immunο-induits chez les patients atteints d'un mélanοme de stade ΙV
    Jean-Matthieu L'Orphelin · 2024 · theses.fr (ABES)
  45. B lymphocytes and autoantibodies in immune-related adverse events following immune checkpoint inhibitors in cancer patients
    Sarah Soussan · 2024
  46. Optimisation immunologique et thérapeutique des doublets de chimio-immunothérapie dans le cancer du sein triple négatif
    Laura Kalfeist · 2024
  47. Défaut de tolérance des lymphocytes B et sa restauration dans les maladies auto-immunes
    Adrien Mirouse · 2024
  48. Trends in Spontaneous Adverse Event Reports Following the Expansion of Pembrolizumab Indications in Japan
    Kana Yamamoto, Ryoko Sakai, Manabu Akazawa · 2026 · YAKUGAKU ZASSHI
  49. Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis
    Karolina Zarańska, Grażyna Kamińska‐Winciorek, Alexander Jorge Cortez, Grażyna Wąsik, Maksymilian Gajda · 2026 · Dermatology and Therapy
  50. A Case of Malignant Pleural Mesothelioma That Developed Vasculitic Neuropathy with Nivolumab Plus Ipilimumab Therapy
    Maki Kajitani, Konomi Kobayashi, 竹下 裕理, Sahoko Imoto, Hikaru Toyota, Satoru Ishii, Naoya Sugimoto, Keiichi Hokkoku, Yuko Sasajima, Hiroyuki Nagase · 2025 · Nihon Naika Gakkai Zasshi
  51. Treatment and outcomes of immunotherapy related colitis and hepatitis- a multi-centre cohort study in the United Kingdom by the National Oncology Trainee Collaborative for Healthcare Research (NOTCH)
    Mirashini Swaminathan, Angelos Angelakas, Mark A Baxter, Jenny Cotton, Caroline Dobeson, Laura Feeney, Abigail Gault, Daniel Johnathan Hughes, Chris Jones, Rebecca J. Lee et al. · 2026 · Supportive Care in Cancer
  52. Immunotherapy: blockade of CTLA-4/B7 and PD-1/PD-L1 pathways in anticancer therapy. Part 2. Clinical aspects
    Andrei A. Shukshin, Artem Rubinstein, А. С. Головкин, О. М. Моисеева, Igor Vladimirovich Kudryavtsev · 2026 · Medical academic journal
  53. A real-world retrospective study of vitiligo associated with immune checkpoint inhibitors based on FAERS and TCGA databases
    Jingchang Ma, Zhibo Cai, Ya Luo, Xiaojun Li, Jinyi Li, Mingjun Hou, Zhu Dingheng · 2026 · Medicine
  54. Cutaneous adverse events due to immune checkpoint inhibitors
    Takafumi Kadono, Tomomitsu Miyagaki · 2026 · Immunological Medicine
  55. Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy
    David Tougeron, Charles Kauffmann, Margherita Ambrosini, Olayidé Boussari, Sara Lonardi, Frank A. Sinicrope, Marwan Fakih, Michael James Overman, Elena Élez, Anthony Turpin et al. · 2026 · Journal for ImmunoTherapy of Cancer
  56. Reactive Cutaneous Capillary Endothelial Proliferation in Esophageal Squamous Cell Carcinoma Patients Treated With Camrelizumab‐Based Therapy: A Pooled Analysis of Two Phase 3 Trials
    Jia Liu, Ye He, Mingming He, Fan Chen, Zhiguo Hou, Zhaoqing Zheng, Chaoyu Lin, Aichun Chen, Ruihua Xu, Huiyan Luo et al. · 2026 · MedComm
  57. Drug‐Induced Vitiligo: FDA Adverse Events Reporting System ( FAERS ) and Canada Vigilance Adverse Reaction ( CAVR ) Database Analysis and Literature Review
    Yuhao Li, Yi Ou, Luyue Chang, Ruiyao Wang, Xinyi Shao, Jingbo Zhang, Jin Chen · 2026 · Journal of Cosmetic Dermatology
  58. Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort Study
    Freya Koffka, Johann Kornowski, Elena Laakmann, Barbara Schmalfeldt, Tim Zell, Glenn Geidel, Christoffer Gebhardt, Pia Roser, Volkmar Müller, Julian Kött · 2026 · International Journal of Cancer
  59. Mortality and Cancer Response in Patients with Immune Check Point Inhibitor Associated Uveitis
    Ryan T. Duong, Matthew A. Oley, Joseph Wright, Abdullah Abou-Samra, Elizabeth Mary Gaughan, Arthi Venkat · 2026 · Ocular Immunology and Inflammation
  60. Vitiligo-like depigmentation as an accessible readout of antitumour immunity in melanoma immunotherapy
    Suhrob Toshev, Dilfuza Jalalova, Gulchekhra Tastanova, Iroda Nurmatova, Ikhtiyor Latipov, Ortiq Ismoilov · 2026 · Clinical & Translational Oncology